The urban airborne vehicle spinout of TU Munich closed more than $240m in funding, in a Tencent-led round reportedly valuing it at up to $1bn.

UC Berkeley's Nurix Therapeutics will use the capital to prepare two protein modulation-based immuno-oncology drugs for the clinic.

Uday Kumar, whose previous spinout iRhythm is trading with a market cap of $2.6bn, has collected $145.6m in a GV-backed round for his latest venture.

The wearable defibrillator developer, founded by Stanford adjunct professor Uday Kumar, has raised more than $145m that will support the launch of its lead product.

Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.

Eli Lilly and WuXi AppTec contributed to what was reportedly a down round for T-cell oncology treatment developer Immunocore following a $320m raise in 2015.

GV and Intel Capital returned to reinvest in the computing technology provider, which was co-founded by Stanford professors and has now raised more than $450m altogether.

Graphcore, which traces its origins back to University of Bristol, has added $150m to a round that already included Ahren Innovation Capital.

D1 Capital Partners has led a series E round for Outset Medical, pushing the OSU dialysis device spinout’s overall funding to more than $430m.

Oak Ridge spinout Verana Health has completed a $100m round led by existing investor GV that will help it expand its clinical database platform into new areas.